BOSTON and LONDON – September 17, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug …
Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BOSTON and LONDON – September 5, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug …
Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
Live moderated webcast on Thursday, September 4th at 4:00 PM ET Access the event here BOSTON and LONDON – September 3, 2025 – Akari Therapeutics, Plc …
[Read more...] about Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Live video webcast on Tuesday, August 19th at 2:00 PM ET BOSTON and LONDON – August 14, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology …
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari’s commitment to continued research to better understand the multiple effects of its …
[Read more...] about Akari Therapeutics Releases Virtual Investor “What This Means” Segment
